EUCTR2017-000358-20-LV进行中（未招募）1 期
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or WithoutTrilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For a patient to be eligible for participation in this study, all of the following criteria must
- •1. Age = 18 years
- •2. Unequivocally confirmed diagnosis of SCLC by histology or cytology, preferably
- •including the presence of neuroendocrine features by immunohistochemistry
- •3. Extensive-stage SCLC
- •4. At least 1 target lesion that is measurable by RECIST v1.1 (Eisenhauer 2009)
- •5. Hemoglobin = 9.0 g/dL
- •6. Absolute neutrophil count (ANC) = 1.5 × 109/L
- •7. Platelet count = 100 × 109/L
- •8. Creatinine = 1.5 mg/dL or glomerular filtration rate (GFR) of = 60 mL/minute
- •9. Total bilirubin = 1.5 × ULN; < 3 × ULN if the patient has documented Gilbert’s disease
- •10. AST and ALT = 2.5 × ULN; = 5 × ULN in the presence of liver metastases
- •11. ECOG performance status of 0 to 2
- •12. Predicted life expectancy of = 3 months
- •13. Contraception:
- •a. For females: All females of childbearing potential must have a negative serum beta human chorionic gonadotropin (ß-hCG) test result
- •at screening. Females must be either postmenopausal, surgically sterile, or agree to use 2 forms of highly effective contraception during the study and for 6 months following discontinuation of study treatment
- •i. Postmenopausal is defined as (1) at least 60 years of age, (2)medically confirmed ovarian failure, or (3) younger than 60 years of ageand have had cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause, and/or
- •serum levels of estradiol and follicle stimulating hormone within the laboratory's reference range for postmenopausal females
- •ii. Acceptable surgical sterilization techniques are complete or partial hysterectomy, bilateral tubal ligation with surgery at least 6 months prior to dosing, or bilateral oophorectomy with surgery at least 2 months prior to dosing
- •iii. Highly effective methods of contraception are those that result in a low failure rate (ie, less than 1% per year) when used consistently and
- •correctly. These include the following:
- •1.Established use of oral, injected or implanted hormonal methods of
- •contraception (stable dose at least 3 months prior to dosing)
- •2. Placement of an intrauterine device or intrauterine system
- •3. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. Barrier methods alone (without spermicide) are not acceptable methods. Likewise, spermicide alone is not an acceptable method
- •4. Male sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). For femalesubjects on the study, the vasectomized male partner should be the sole partner for that subject
- •5. True abstinence, when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- •b. For males: For males: Males must be surgically sterile or have a female partner who is either postmenopausal, surgically sterile, or using
- •2 forms of highly effective contraception as noted above. Acceptable surgical sterilization techniques are vasectomy with surgery at least 6 months prior to dosing. Males must also refrain from sperm donation during the study and for 6 months following discontinuation of treatment
- •14. Able to understand and sign an informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18
排除标准
- •A patient will not be eligible for participation in this study if any of the following criteria
- •1. Limited-stage SCLC
- •2. Prior chemotherapy for limited or extensive-stage SCLC
- •3. Prior treatment with immunotherapies including but not limited to cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies (such as anti-PD-1, anti-PD-L1, CTLA4 therapeutic antibodies)
- •4. Presence of symptomatic brain metastases requiring immediate treatment with radiation therapy or steroids
- •5. Malignancies other than SCLC within 3 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
- •6. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan (history of radiation pneumonitis in the radiation field [fibrosis] is permitted)
- •7. Active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Exceptions include vitiligo, controlled asthma, type I diabetes, Graves’ disease, Hashimoto’s disease, or with medical monitor approval. Stable replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) for well-controlled disease is not
- •considered a form of systemic treatment.
- •8. Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart failure
- •(Class III or IV as defined by the New York Heart Association [NYHA] functional classification system)
- •9. Known history of stroke or cerebrovascular accident within 6 months prior to enrollment
- •10. Serious active infection at the time of enrollment
- •11. Psychiatric illness/social situations that would limit study compliance
- •12. Other uncontrolled serious chronic disease or conditions that in the investigator’s opinion
- •could affect compliance or follow-up in the protocol
- •13. Known human immunodeficiency virus (HIV), known active Hepatitis B (eg, HBsAg
- •reactive or HBV DNA detected) or Hepatitis C (eg, HCV RNA [qualitative] is detected)
- •14. Radiotherapy to any site within 2 weeks prior to enrollment
- •15. Receipt of any investigational medication within 4 weeks prior to enrollment
- •16. Administration of a live attenuated vaccine within 4 weeks before enrollment or anticipation that such a live attenuated vaccine will be required during the study
- •17. Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine (eg, FluMist) within 4 weeks prior to enrollment, at any time during the study, and at least 5 months after the last dose of atezolizumab
- •18. Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide,
- •and anti-tumor necrosis factor [TNF] agents) within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- •19. Hypersensitivity to any of the components of the formulation of etoposide or etoposide phosphate
- •20. Hypersensitivity to carboplatin or
研究者
相似试验
进行中（未招募）
1 期
Study of Carboplatin, Etoposide, and Atezolizumab With or WithoutTrilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small Cell Lung CancerEUCTR2017-000358-20-BGG1 Therapeutics100
进行中（未招募）
1 期
Study of Carboplatin, Etoposide, and Atezolizumab With or WithoutTrilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small Cell Lung Cancerntreated Extensive-Stage Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000358-20-EEG1 Therapeutics100
进行中（未招募）
1 期
Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small Cell Lung CancerEUCTR2017-000358-20-ESG1 Therapeutics100
进行中（未招募）
1 期
Study of Carboplatin, Etoposide, and Atezolizumab With or WithoutTrilaciclib (G1T28) in Patients with Untreated Extensive-Stage Small Cell Lung Cancerntreated Extensive-Stage Small Cell Lung CancerMedDRA version: 20.0Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000358-20-FRG1 Therapeutics100
招募中
2 期
A phase II study of atezolizumab plus chemotherapy for elderly patients with ED-SCLCSmall cell lung cancerJPRN-jRCTs041210002Takahashi Toshiaki40